The role of fibrinolytic system components in thrombus formation and removal in vivo was investigated in groups of six mice deficient in urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA), or plasminogen activator inhibitor-1 (PAI-1) (u-PA-/-, t-PA-/- or PAI-1-/-, respectively) or of their wild type controls (u-PA+/+, t-PA+/+ or PAI-1+/+). Thrombus was induced in the murine carotid artery by endothelial injury using the photochemical reaction between rose bengal and green light (540 nm). Blood flow was continuously monitored for 90 min on day 0 and for 20 min on days 1, 2 and 3. The times to occlusion after the initiation of endothelial injury in u-PA+/+, t-PA+/+ or PAI-1+/+ mice were 9.4 ± 1.3, 9.8 ± 1.1 or 9.7 ± 1.6 min, respectively. u-PA-/- and t-PA-/- mice were indistinguishable from controls, whereas that of PAI-1-/- mice were significantly prolonged (18.4 ± 3.7 min). Occlusion persisted for the initial 90 min observation period in 10 of 18 wild type mice and was followed by cyclic reflow and reocclusion in the remaining 8 mice. At day 1, persistent occlusion was observed in 1 wild type mouse, 8 mice had cyclic reflow and reocclusion and 9 mice had persistent reflow. At day 2, all injured arteries had persistent reflow. Persistent occlusion for 90 min on day 0 was observed in 3 u-PA-/-, in all t-PA-/- mice at day 1 and in 2 of the t-PA-/-mice at day 2 (p <0.01 versus wild type mice). Persistent patency was observed in all PAI-1-/- mice at day 1 and in 5 of the 6 u-PA-/- mice at day 2 (both p <0.05 versus wild type mice). In conclusion, t-PA increases the rate of clot lysis after endothelial injury, PAI-1 reduces the time to occlusion and delays clot lysis, whereas u-PA has little effect on thrombus formation and spontaneous lysis.
References
1
Fuster V.
Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-46.
2
Matsuo O,
Rijken DC,
Collen D.
Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 1981; 291: 590-1.
3
Matsuo O,
Banjo H,
Okada K,
Tanaka K,
Sucked M,
Ida Y,
Armour H.
Thrombolytic effect of single-chain pro-urokinase in a rabbit jugular vein thrombosis model. Thromb Res. 1986; 42: 187-94.
6
Okada K,
Ueshima S,
Takaishi T,
Yuasa H,
Fukao H,
Matsuo O.
Effect of fibrin and α2-antiplasmin on plasminogen activation by staphylokinase. Am J Hematol 1996; 53: 151-7.
7
Levi M,
Biemond BJ,
van Zonneveld AJ,
ten Cate JW,
Pannekoek H.
Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-12.
8
Braaten JV,
Handt S,
Jerome WG,
Kirkpatrick J,
Lewis JC,
Hantgan RR.
Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-9.
9
Stringer HA,
van Swieten P,
Heijnen HF,
Sixma JJ,
Pannekoek H.
Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 14: 1452-8.
10
Kunitada S,
FitzGerald GA.
Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992; 79: 1420-7.
11
Matsuno H,
Uematsu T,
Nagashima S,
Nakashima M.
Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Meth 1991; 25: 303-17.
12
Matsuno H,
Uematsu T,
Umemura K,
Takiguchi Y,
Wada K,
Nakashima M.
Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator. Br J Pharmacol 1992; 106: 533-8.
13
Hirata Y,
Takiguchi Y,
Wada K,
Matsuno H,
Umemura K,
Uematsu T,
Nakashima M.
Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig. Eur J Pharmacol 1993; 231: 421-5.
14
Takiguchi Y,
Shimazawa M,
Nakashim M.
A comparative study of the anti-thrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea pigs. Br J Pharmacol 1996; 118: 1633-8.
16
Carmeliet P,
Schoonjans L,
Kieckens L,
Ream B,
Degen J,
Bronson R,
De Vos R,
van den Oord JJ,
Collen D,
Mulligan RC.
Physiological consequence of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
17
Carmeliet P,
Stassen JM,
Schoonjans L,
Ream B,
van den Oord JJ,
De Mol M,
Mulligan RC,
Collen D.
Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-60.
19
Ploplis VA,
Carmeliet P,
Vazirzadeh S,
Van Vlaenderen I,
Moons L,
Plow EF,
Collen D.
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995; 92: 2585-93.
20
Matsuno H,
Kozawa O,
Niwa M,
Kaida T,
Hayashi H,
Uematsu T.
GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster. Br J Pharmacol 1997; 122: 1099-104.
21
DeWood MA,
Spores J,
Notske R,
Mouser LT,
Burroughs R,
Golden MS,
Lang HT.
Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
22
Boehrer JD,
Glamann DB,
Lange RA,
Willard JE,
Brogan WC,
Eichhorn EJ,
3rd
Grayburn PA,
Anwar A,
Hillis LD.
Effect of coronary angioplasty on late potentials one to two weeks after acute myocardial infarction. Am J Cardiol 1992; 70: 1515-9.
23
Simes RJ,
Topol EJ,
Holmes DR,
White Jr HD,
Rutsch WR,
Vahanian A,
Simoons ML,
Morris D,
Betriu A,
Califf RM.
et al Link between the angio-graphic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91: 1923-8.
24
Strickland S,
Reich E,
Sherman I M.
Plasminogen activator in early embryo-genesis: enzyme production by trophoblast and parietal endoderm. Cell 1976; 9: 231-40.
25
Rifkin DB,
Moscatelli D,
Bizik J,
Quarto N,
Blei F,
Dennis P,
Flaumenhaft R,
Mignatti P.
Growth factor control of extracellular proteolysis. Cell Diff Devel 1990; 32: 313-8.
28
Marsh JJ,
Konopka RG,
Lang IM,
Wang HY,
Pedersen C,
Chiles P,
Reilly CF,
Moser KM.
Suppression of thrombolysis in a canine model of pulmonary embolism. Circulation 1994; 90: 3091-7.
30
Lee MH,
Vosburgh E,
Anderson K,
McDonagh J.
Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81: 2357-62.
